Case VII — Deceased
Deron Wells
Southern California · Cigna · Stage 4 Lung Cancer · Double-Lung Transplant
Deron Wells died in June 2025. He was 59. He leaves behind a wife and three children. His appeal was eventually approved. He died anyway. This is the case that makes the argument for provisional coverage during appeal — because winning the appeal is not enough if the delay has already cost you your window.
The Story
Deron Wells was battling stage 4 lung cancer and needed a double-lung transplant — a procedure being offered through a clinical trial at Northwestern Medicine in Chicago. UCLA Santa Monica Medical Center had prepared him for transport. Cigna had already approved the airlift procedures that would get him there.
As Wells and his wife were preparing to leave for Chicago, Cigna denied coverage for the transplant itself. The insurer's stated grounds: the procedure was not a standard treatment for lung cancer, and Cigna does not cover clinical trials.
The story went viral. Public pressure mounted. Cigna's denial was appealed — and eventually overturned. Wells was flown to Chicago and placed on the transplant list. A donor was found. But by then, his health had deteriorated to the point where doctors could not proceed. He was largely sedated. His condition made him a priority on the list. He died just days after being relisted — having won the fight to get there, and running out of time anyway.
The Mechanism — Approved the Airlift. Denied the Transplant.
Cigna's decision contains a specific cruelty worth naming: the insurer approved the logistics of getting Deron Wells to Chicago — the airlift, the transfer — but denied the procedure those logistics existed to enable. The family was preparing to leave. The approval of the airlift had implied, reasonably, that approval of the transplant would follow. It did not.
The denial on "clinical trial" grounds is a documented pattern. Insurers routinely exclude clinical trial coverage even when those trials represent the only available treatment pathway for a terminal diagnosis. In Wells' case, the transplant was not experimental in the sense of being unproven — it was the medically appropriate response to his condition, delivered in a trial setting because that was the mechanism by which it was being offered at that institution.
Timeline
Wells undergoes months of treatment for stage 4 lung cancer at UCLA Santa Monica. Doctors identify Northwestern Medicine's clinical trial as the viable path to a double-lung transplant. Cigna approves airlift procedures for transfer to Chicago.
As Wells and his wife prepare to leave UCLA Santa Monica, Cigna denies coverage for the transplant itself — citing that it is not standard treatment for lung cancer and that the insurer does not cover clinical trials. The story goes viral.
Public pressure and viral coverage accelerate the appeal. Cigna's denial is overturned. Wells is flown to Chicago and placed on the transplant list at Northwestern Medicine.
A donor becomes available. Wells' health has deteriorated during the delay. Doctors are unable to proceed with the transplant. He is largely sedated. His critical condition makes him a priority on the transplant list again.
Deron Wells dies — just days after being relisted. He was 59. His wife and three children survive him. His friend Scott Kern: "In his death, there is hope that things can change and that next patient will get that care in time so that their 11-year-old son doesn't grow up without a daddy."
Why This Case Is the Argument for § 3 — The Patient Safety Buffer Fund
Most cases on this page argue for § 5 — the Malpractice Trigger that holds reviewing physicians accountable. Deron Wells' case argues for § 3: provisional coverage during the appeals process, funded by the insurer whose denial created the need for appeal.
Wells won his appeal. The system worked — technically. But he died in the gap between denial and approval. Under the Clinical Integrity Amendment's Buffer Fund, provisional coverage would have been granted the moment his treating physicians submitted a medical necessity override. He would have been in Chicago while Cigna was still deliberating. The outcome may have been different. We cannot know. What we know is that it would not have been decided by the pace of Cigna's appeal review.
See § 3 — The Patient Safety Buffer Fund in The Remedy Room →Has this happened to you?
Every documented case adds to the evidentiary record. Your story matters.